Vaccines for Pandemic Influenza pp 109-132

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 333)

Live Attenuated Vaccines for Pandemic Influenza



In this chapter, we will review the development of and clinical experience with the currently licensed seasonal live attenuated influenza vaccines (LAIV) and preclinical studies of H5, H7, and H9 live attenuated pandemic influenza vaccine candidates. Vectored vaccine approaches will not be reviewed in this chapter. Experience with seasonal influenza vaccination has demonstrated the safety and efficacy of LAIV in both children and adults; moreover, cross-protection among antigenically distinct viruses within the same subtype may be induced by LAIV. While clinical studies and further characterization of the immunologic response to avian influenza viruses are still needed, the experience with seasonal LAIV underscores the potential of live attenuated vaccines to play an important role in the event of a pandemic.


live attenuated influenza vaccines pandemic Plasmid-based reverse genetics techniques 



Avian influenza


Avian influenza virus




50% Egg infectious dose




Hemagglutination inhibition


50% Human infectious dose






Live attenuated influenza vaccine


50% Lethal dose


Master donor virus


50% Mouse infectious dose




Plaque-forming units


50% Tissue culture infectious dose


Trivalent inactivated vaccine






  1. Alexandrova G, Smorodintsev A. (1965) Obtaining of an additionally attenuated vaccinating cryophilic influenza strain. Rev Rown Inframicrobiol 2:179–189Google Scholar
  2. Ali M, Maassab HF, Jennings R, Potter CW. (1982) Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann Arbor/6/60. Infect Immun 38(2):610–619PubMedGoogle Scholar
  3. Armerding D, Rossiter H, Ghazzouli I, Liehl E. (1982) Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis 145(3):320–323PubMedGoogle Scholar
  4. Ashkenazi S, Vertruyen A, Arístegui J, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:870CrossRefPubMedGoogle Scholar
  5. Banks J, Speidel E, Alexander DJ. (1998) Characterisation of an avian influenza A virus isolated from a human is an intermediate host necessary for the emergence of pandemic influenza viruses? Arch. Virol 143:781–787CrossRefGoogle Scholar
  6. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M. (1998) The efficacy of live attenuated, cold adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338:1405–1412CrossRefPubMedGoogle Scholar
  7. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M. (2000a) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181(3):1133–1137CrossRefGoogle Scholar
  8. Belshe RB, Gruber WC, Mendelman PM. (2000b) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168–175CrossRefGoogle Scholar
  9. Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM. (2004) Safety, efficacy, and effectiveness of live attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis 39(7):920–927CrossRefPubMedGoogle Scholar
  10. Belshe RB, Edwards KM, Vesikari T, Black SV,Walker RE, Hultquist M, Kemble G, Connor E. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356(7):685–696CrossRefPubMedGoogle Scholar
  11. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20(9–10):1340–1353CrossRefPubMedGoogle Scholar
  12. Boyce TG, Gruber WC, Coleman-Dockery SD, Sannella EC, Reed GW, Wolff M, Wright PF. (1999) Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18(1–2):82–88CrossRefPubMedGoogle Scholar
  13. Buonagurio DA, O’Neill RE, Shutyak L, D’Arco GA, Bechert TM, Kazachkov Y, Wang HP, DeStefano J, Coelingh KL, August M, Parks CL, Zamb TJ, Sidhu MS, Udem SA. (2006) Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 347(2):296–306CrossRefPubMedGoogle Scholar
  14. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS, Guan Y. (2005) Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 43(11):5760–5767CrossRefPubMedGoogle Scholar
  15. Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. (2000) Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38(2):839–845PubMedGoogle Scholar
  16. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K. (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21(27–30):4430–4436CrossRefPubMedGoogle Scholar
  17. Chen Z, Aspelund A, Kemble G, Jin H. (2006) Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 345(2):416–4123CrossRefPubMedGoogle Scholar
  18. Clements ML, Murphy BR. (1986) Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23(1):66–72PubMedGoogle Scholar
  19. Clements ML, Tierney EL, Murphy BR. (1985) Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine. J Clin Microbiol 21(6):997–999PubMedGoogle Scholar
  20. Clements ML, Betts RF, Tierney EL, Murphy BR. (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24(1):157–160PubMedGoogle Scholar
  21. Cox NJ, Kitame F, Kendal AP, Massab HF, Naeve C. (1988) Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 167:553–567Google Scholar
  22. Delem A. (1977) Protective efficacy of RIT 4025, a live attenuated influenza vaccine strain, and evaluation of heterotypic immunity to influenza A viruses in ferrets. J Hyg 79(2):203–208CrossRefGoogle Scholar
  23. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24(47–48):6859–6866CrossRefPubMedGoogle Scholar
  24. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169(1):68–76PubMedGoogle Scholar
  25. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. (1999) Rescue of influenza A virus from recombinant DNA. J Virol 73:9679–9682PubMedGoogle Scholar
  26. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 101(5):1356–1361CrossRefPubMedGoogle Scholar
  27. Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J. (2007) The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 26(7):956–965CrossRefPubMedGoogle Scholar
  28. Garmashova L, Plezhaev F, Alexandrova G. (1984) Cold-adapted A/Leningrad/134/47/57 (H2N2) strain, a specific donor of attenuation of live influenza vaccine for children, and recombinants based on its base. Vopr Virusol 29:28–31PubMedGoogle Scholar
  29. Guo Y, Li J, Cheng X. (1999) Discovery of men infected by avian influenza H9N2 virus. China J Exp Virology 13(2):105–108Google Scholar
  30. Hatta M, Gao P, Halfmann P, Kawaoka Y. (2001) Molecular basis for high viruleunce of Hong Kong H5N1 influenza A viruses. Science 293(5536):1840–1842CrossRefPubMedGoogle Scholar
  31. Hirst M, Astell CR, Griffith M, Coughlin SM, Moksa M, Zeng T, Smailus DE, Holt RA, Jones S, Marra MA, Petric M, Krajden M, Lawrence D, Mak A, Chow R, Skowronski DM, Tweed SA, Goh S, Brunham RC, Robinson J, Bowes V, Sojonky K, Byrne SK, Li Y, Kobasa D, Booth T, Paetzel M. (2004) Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 10(12):2192–2195PubMedGoogle Scholar
  32. Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. (2000) “Ambisense” approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267(2):310–317CrossRefPubMedGoogle Scholar
  33. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. (2002a) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20(25–26):3165–3170CrossRefGoogle Scholar
  34. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. (2002b) Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci USA 99(17):11411–11416CrossRefGoogle Scholar
  35. Hoffmann E, Mahmood K, Chen Z, Yang CF, Spaete J, Greenberg HB, Herlocher ML, Jin H, Kemble G. (2005) Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 79(17):11014–11021CrossRefPubMedGoogle Scholar
  36. Horimoto T, Kawaoka Y. (1994) Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 68(5):3120–3128PubMedGoogle Scholar
  37. Horimoto T, Kawaoka Y. (2001) Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 14(1):129–149CrossRefPubMedGoogle Scholar
  38. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, Chang S, Braun MM, Ball R. (2005) Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 294(21):2720–2725CrossRefPubMedGoogle Scholar
  39. Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang CF, Kemble G, Greenberg H. (2003) Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains derived from cold-adapted A/Ann Arbor/6/60. Virology 306(1):18–24CrossRefPubMedGoogle Scholar
  40. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. (1986) Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154(1):121–127PubMedGoogle Scholar
  41. Karron RA, Steinhoff MC, Subbarao EK, Wilson MH, Macleod K, Clements ML, Fries LF, Murphy BR. (1995) Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 14(1):10–16PubMedCrossRefGoogle Scholar
  42. Keitel WA, Piedra PA. (1998) Live cold-adapted, reassortant influenza vaccines. In: Nicholson K, Webster RG, Hay AJ (eds) Textbook of influenza. Blackwell, MaldenGoogle Scholar
  43. Kendal AP. (1997) Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur J Epidemiol 13(5):591–609CrossRefPubMedGoogle Scholar
  44. Kermode-Scott B. (2004) WHO confirms avian flu infections in Canada. BMJ 328(7445):913CrossRefPubMedGoogle Scholar
  45. Klenk HD, Garten W. (1994) Host cell proteases controlling virus pathogenicity. Trends Microbiol 2(2):39–34CrossRefPubMedGoogle Scholar
  46. Klimov AI, Cox NJ, Yotov WV, Rocha E, Alexandrova GI, Kendal AP. (1992) Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus. Virology 186(2):795–797CrossRefPubMedGoogle Scholar
  47. Klimov AI, Egorov AY, Gushchina MI, Medvedeva TE, Gamble WC, Rudenko LG, Alexandrova GI, Cox NJ. (1995) Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza virus: sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children. J Gen Virol 76(Pt 6):1521–1525CrossRefPubMedGoogle Scholar
  48. Klimov A, Rudenko LG, Egorov AY, Romanova JR, Polezhaev FI, Alexandrova GI, Cox NJ. (1996) Genetic stability of Russian cold-adapted live attenuated reassortant influenza vaccines. In: Brown L, Hampson A, Webster R. (eds) Options for the control of influenza III. Elsevier, Amsterdam, pp 129–136Google Scholar
  49. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363(9409):587–593CrossRefPubMedGoogle Scholar
  50. Kurtz J, Manvell RJ, Banks J. (1996) Avian influenza virus isolated from a woman with conjunctivitis. Lancet 348:901–902CrossRefPubMedGoogle Scholar
  51. Li S, Liu C, Klimov A, Subbarao K, Perdue ML, Mo D, Ji Y, Woods L, Hia S, Bryant M. (1999) Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 179(5):1132–1138CrossRefPubMedGoogle Scholar
  52. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N, Hay A. (2000) Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 97(17):9654–9658CrossRefPubMedGoogle Scholar
  53. Luke CJ, Subbarao K. (2006) Vaccines for pandemic influenza. Emerg Infect Dis 12 (1):66–72PubMedGoogle Scholar
  54. Massab HF. (1967) Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 213(5076):612–614CrossRefGoogle Scholar
  55. Massab HF. (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102(3):728–732Google Scholar
  56. Massab HF, Bryant ML. (1999) The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9(4):237–244CrossRefGoogle Scholar
  57. Massab HF, Kendal AP, Abrams GD, Monto AS. (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 146(6):780–790Google Scholar
  58. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BD. (2004) Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002–like H3N2 antigenic variant strain. Pediatr Infect Dis J (11):1053–1055Google Scholar
  59. Murphy B, Coelingh K. (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15(2):295–323CrossRefPubMedGoogle Scholar
  60. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J. (1999) Effectiveness of live attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282(2):137–144CrossRefPubMedGoogle Scholar
  61. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez D, Donis R, Hoffmann E, Hobom G, Kawaoka Y. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96:9345–9350CrossRefPubMedGoogle Scholar
  62. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355(24):2513–2512CrossRefPubMedGoogle Scholar
  63. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF. (1999) Human infection with influenza H9N2. Lancet 354(9182):916–917CrossRefPubMedGoogle Scholar
  64. Perdue ML, Garcia M, Senne D, Fraire M. (1997) Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res (1997) 49(2):173–86CrossRefPubMedGoogle Scholar
  65. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. (2007) Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 178(2):1030–1038PubMedGoogle Scholar
  66. Powers DC, Murphy BR, Fries LF, Adler WH, Clements ML. (1992) Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 40(2):163–167PubMedGoogle Scholar
  67. Puzelli S, DiTrani L, Fabiani C, Campitelli L, De Marco MA, Capua I, Aguilera JF, Zambon M, Donatelli I. (2005) Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis 192(8):1318–1322CrossRefPubMedGoogle Scholar
  68. Richt JA, Lekcharoensuk P, Lager KM, Vincent AL, Loiacono CM, Janke BH, Wu WH, Yoon KJ, Webby RJ, Solórzano A, García-Sastre A. (2006) Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J Virol 80(22):11009–11018CrossRefPubMedGoogle Scholar
  69. Rudenko LG, Lonskaya NI, Klimov AI, Vasilieva RI, Ramirez A. (1996) Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3–14-year-olds. Bull World Health Organ 74(1):77–84PubMedGoogle Scholar
  70. Subbarao K, Joseph T. (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7(4):267–278CrossRefPubMedGoogle Scholar
  71. Subbarao K, Katz JM. (2004) Influenza vaccines generated by reverse genetics. Curr Top Microbiol Immunol 283:313–342PubMedGoogle Scholar
  72. Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. (2006) Live attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3(9):e360CrossRefPubMedGoogle Scholar
  73. Talon J, Salvatore M, O’Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P. (2000) Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci USA 97(8):4309–4314CrossRefPubMedGoogle Scholar
  74. Treanor JJ, Roth FK, Betts RF. (1990) Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J Clin Microbiol 28(3):596–599PubMedGoogle Scholar
  75. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M. (1999) Evaluation of trivalent, live, cold-adapted and inactivated influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18(9–10):899–906CrossRefPubMedGoogle Scholar
  76. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Kraiden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. (2004) Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10(12):2196–2199PubMedGoogle Scholar
  77. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O’Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B. (2006) A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25(7):590–595CrossRefPubMedGoogle Scholar
  78. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, García-Sastre A, Richt JA. (2007) Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25(47):7999–8009CrossRefPubMedGoogle Scholar
  79. Watanabe T, Watanabe S, Kim JH, Hatta M, Kawaoka Y. (2007) A novel approach to the development of effective H5N1 influenza A virus vaccines: the use of M2 cytoplasmic tail mutants. J Virol 82(5):2486–2492CrossRefPubMedGoogle Scholar
  80. Webster RG, Geraci J, Petursson G, Skirnisson K. (1981) Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med 304:911PubMedGoogle Scholar
  81. Wright PF, Neumann G, Kawaoka Y. (2007) Orthomyxoviruses. In: Howley PM, Knipe DM (eds) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1691–1740Google Scholar
  82. Youngner JS, Treanor JJ, Betts RF, Whitaker-Dowling P. (1994) Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J Clin Microbiol 32(3):750–4PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.NIAID, NIHBethesdaUSA
  2. 2.Laboratory of Infectious DiseasesNIAID, NIHBethesdaUSA

Personalised recommendations